QuickMIC® installation for clinical routine use in Central Eastern Europe
The diagnostics company Gradientech today announces that Biomedica Medizinprodukte GmbH, its appointed distributor for Austria, Switzerland, and Central Eastern Europe, has acquired its first customer for QuickMIC® in clinical routine use.
A university hospital in the Central Eastern Europe market has now started to implement the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) in clinical routine, to use it in their program for hospital-acquired infections.
“This is a significant milestone in our partnership together with Gradientech to implement the QuickMIC system in the hospital market in Central Eastern Europe. Effective management of hospital-acquired infections is a crucial part where the QuickMIC AST system will fill an important gap with its precision and short time to result. From Biomedica we see high interest and great ambition of hospitals in our markets to implement new diagnostic solutions to improve the management of critically ill patients, where the modular set-up and scalability of QuickMIC is an additional clear advantage. This is just the start, and I´m looking forward to more installations in near future,” says Avdo Novalija, Business Development at Biomedica Medizinprodukte GmbH.
”It is very encouraging to see the fast progress into clinical routine that Biomedica is achieving with QuickMIC. We see rapid AST being high up on the agendas for hospital settings in the eastern and southern parts of Europe where antimicrobial resistance levels are generally high. I look forward with confidence to future announcements from hospitals in Europe soon,” says AnnaLotta Schiller, Chief Commercial Officer at Gradientech.
The QuickMIC system's ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance on the right antibiotic in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO AnnaLotta Schiller, PhD, CCO
Tel: +46 736 29 35 80 Tel: +46 733 42 32 93
sara.thorslund@gradientech.se annalotta.schiller@gradientech.se
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
